Gupta, Milan
Wani, Rajvi J.
Al Faraidy, Khalid
Bergeron, Jean
Contreras, Eduardo
Peña, Angel Alberto Garcia
Mancini, G. B. John
Padilla, Francisco
Lopez, Abel Alberto Pavia
Philip, Kiran
Wu, Johnny
Mackinnon, Erin S.
Funding for this research was provided by:
Amgen
Article History
Received: 2 August 2023
Accepted: 21 September 2023
First Online: 7 October 2023
Declarations
:
: Authors report the following potential conflicts of interest for grants/contracts/consulting fees/honoraria/support for attending meetings or travel/participation on a data safety monitoring board or advisory board. Milan Gupta: Amgen; Khalid Al Faraidy: None declared; Jean Bergeron: Amarin, Amgen, Amryt, ArrowHead, Eli Lilly, HLS Therapeutics, Ionis Pharmaceuticals Inc., Kowa, LIB Therapeutics, Medison, Novartis, Novo Nordisk, Regeneron, Sanofi, The Medicine Co., Ultragenyx; Eduardo Contreras: None declared; Angel Alberto Garcia Peña: Amgen, AstraZeneca, Boehringer, Novartis, Procaps, Pfizer, Sanofi; G. B. John Mancini: Amgen, Esperion, HLS Therapeutics, Novartis, Pfizer, Sanofi; Francisco Padilla: Amgen, Asofarma, AstraZeneca, Ferrer, Servier, Silanes; Abel Alberto Pavia Lopez: Amgen, Ferrer, Novartis, Novo Nordisk, Servier, Stendal, Viatris; Johnny Wu is an employee of Amgen, Inc.; Kiran Philip is an employee of and owns stock in Amgen, Inc.; Rajvi J. Wani and Erin S. Mackinnon are employees of and own stock in Amgen Canada, Inc.
: The study was conducted in accordance with the Declaration of Helsinki and the study protocol was reviewed and approved by each site’s institutional review board/institutional ethics committee (full list provided in Supplementary Material online). All participants were required to sign an informed consent form for inclusion in the study.